Audentes Therapeutics (BOLD) Sees Strong Trading Volume
Audentes Therapeutics Inc (NASDAQ:BOLD) saw strong trading volume on Friday . 827,238 shares were traded during trading, an increase of 78% from the previous session’s volume of 464,963 shares.The stock last traded at $36.13 and had previously closed at $34.10.
A number of equities analysts recently commented on the company. Raymond James Financial restated a “hold” rating on shares of Audentes Therapeutics in a report on Thursday, January 4th. BMO Capital Markets set a $44.00 target price on Audentes Therapeutics and gave the company a “buy” rating in a report on Friday, January 5th. William Blair reiterated a “buy” rating on shares of Audentes Therapeutics in a research note on Friday, January 5th. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 22nd. Finally, Wedbush lifted their price objective on Audentes Therapeutics to $56.00 and gave the company an “outperform” rating in a research note on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $34.00.
The firm has a market cap of $1,317.59, a P/E ratio of -10.35 and a beta of 0.89.
Several institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC purchased a new position in shares of Audentes Therapeutics in the 4th quarter valued at about $248,000. Teachers Advisors LLC boosted its stake in shares of Audentes Therapeutics by 12.7% in the 4th quarter. Teachers Advisors LLC now owns 30,347 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 3,421 shares during the period. Two Sigma Investments LP lifted its stake in Audentes Therapeutics by 277.0% during the fourth quarter. Two Sigma Investments LP now owns 128,707 shares of the biotechnology company’s stock worth $4,022,000 after purchasing an additional 94,565 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in Audentes Therapeutics during the fourth quarter worth approximately $516,000. Finally, Goldman Sachs Group Inc. lifted its stake in Audentes Therapeutics by 433.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 80,097 shares of the biotechnology company’s stock worth $2,503,000 after purchasing an additional 65,092 shares during the last quarter. Institutional investors and hedge funds own 67.36% of the company’s stock.
WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/audentes-therapeutics-bold-sees-strong-trading-volume/1907344.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.